Our findings here support the prior study on HRD1, proteostasis regulators, and genetic epilepsies and suggest that this class of drug could be repurposed for at least a subset of epilepsies caused by mutations like GABRG2(Q390X). The gene discussed is SYVN1; the disease is epilepsy.